Premium
PPAR‐γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow
Author(s) -
Zhang HuiFeng,
Wang Li,
Yuan HuiJuan,
Ma YueHua,
Wang YanFang,
Hu ZiYing,
Su Yong,
Zhao ZhiGang
Publication year - 2013
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.10046
Subject(s) - pioglitazone , agonist , bone marrow , progenitor cell , apoptosis , chemistry , endothelial progenitor cell , microbiology and biotechnology , cancer research , pharmacology , endocrinology , medicine , biology , receptor , stem cell , biochemistry , diabetes mellitus , type 2 diabetes
Selective peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) agonist affects the functions of endothelial progenitor cells (EPCs). This study explores the effect of selective PPAR‐γ agonist, pioglitazone, on EPC apoptosis. The cells were cultured and identified via the double staining method in a medium containing different concentrations of pioglitazone. EPC apoptosis was detected by flow cytometry. On Day 7, EPCs engulfed DiL‐ac‐LDL and FITC‐UEA‐1, and showed yellow fluorescence in a laser‐scanning confocal microscope. EPC apoptosis inhibition was maximal at 50 µmol/L. The ability of pioglitazone to prevent EPC apoptosis may be mediated by the PI3K/Akt signal pathway. The use of thiazolidine two ketone (TZD) to reduce EPC apoptosis may have some potential in treating vascular diseases.